Article
Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study.
Clinical and translational science - 1 Jun 2023
Ekman Simon, Cselényi Zsolt, Varrone Andrea, Jucaite Aurelija, Martin Heather, Schou Magnus, Johnström Peter, Laus Gianluca, Lewensohn Rolf, Brown Andrew P, van der Aart Jasper, Vishwanathan Karthick, Farde Lars
Abstract excerpt
Brain metastases (BMs) are associated with poor prognosis in epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). Osimertinib is a third-generation, irreversible, EGFR-tyrosine kinase inhibitor that potently and selectively inhibits EGFR-sensitizing and T790M resistance mutations with efficacy in EGFRm NSCLC including central nervous system (CNS) metastases. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.